The Evaluation Of Use of Belimumab in Routine Care SEttings in Lupus Nephritis (LN): the OBSErve-LN Study
GlaxoSmithKline
Summary
The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservation in belimumab treated participants.
Description
This is a Phase 4 study and will involve both prospective and retrospective data collection from participants.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participants to provide a signed informed consent at the time of enrollment per protocol, * Male or female aged 18 or over at initiation of belimumab, * Participants received belimumab in any formulation (subcutaneous or intravenous) for the treatment of active LN prescribed as per local label in combination with standard immunosuppressive therapy/ies at initiation of belimumab, * Participants initiated belimumab 6 to 24 months prior to study enrollment, * Accessibility of medical records starting at belimumab initiation (including accessibility of medical records for th…
Interventions
- OtherNone (Observational study)
Not Applicable since Observational Study
Locations (5)
- GSK Investigational SiteBaltimore, Maryland
- GSK Investigational SiteCharlotte, North Carolina
- GSK Investigational SiteColumbus, Ohio
- GSK Investigational SiteHixson, Tennessee
- GSK Investigational SiteFukuoka